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Abstract
Background:  Congenital nephrogenic diabetes insipidus (NDI) is a rare X-linked inherited
disorder characterized by the excretion of large volumes of diluted urine and caused by mutations
in arginine vasopressin receptor 2 (AVPR2) gene. To investigate the mutation of AVPR2 gene in a
Chinese family with congenital NDI, we screened AVPR2 gene in two NDI patients and eight family
members by PCR amplification and direct sequencing.
Results:  Five specific fragments, covering entire coding sequence and their flanking intronic
sequences of AVPR2 gene, were not observed in both patients, while those fragments were all
detected in the control subjects. Several different fragments around the AVPR2 locus were
amplified step by step. It was revealed that a genomic fragment of 5,995-bp, which contained the
entire AVPR2 gene and the last exon (exon 22) of the C1 gene, was deleted and a 3-bp (GAG) was
inserted. Examination of the other family members showed that the mothers and the grandmother
were carriers for this deletion.
Conclusion:  Our findings suggest that the two patients in a Chinese family suffering from
congenital NDI had a 5,995-bp deletion and 3-bp (GAG) insertion at Xq28. The deletion contained
the entire AVPR2 gene and exon 22 of the C1 gene.
Background
Congenital nephrogenic diabetes insipidus (NDI) is a rare
inherited disorder characterized by the excretion of large
volumes of diluted urine resulting from resistance of the
renal collecting duct to the antidiuretic hormone arginine
vasopressin (AVP), and the clinical characteristics include
polyuria, polydipsia, fever, hypernatremic dehydration,
and constipation. Ninety percent of congenital NDI are
linked to the X-chromosome and are caused by loss-of-
function mutations in the arginine vasopressin type 2
receptor (AVPR2) gene. Since human AVPR2 gene was
cloned successfully in 1992, more than 190 distinct dis-
ease-causing mutations in AVPR2 gene have been identi-
fied in X-linked congenital NDI families[1]. The
mutations consist of missense, nonsense, frameshift,
splice-site, insertion, and deletion mutations. These muta-
tions are not concentrated on one domain of the receptor,
but are scattered throughout the protein, except for the
part coding of the N- and C-terminal tails of the receptor.
The phenomenon of so many mutations in AVPR2 gene in
NDI patients indicates that this disease is highly heteroge-
neous at the molecular level. Among these mutations, the
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vast majority result in single amino acid substitutions
(missense mutations) or receptor truncations caused by
nonsense or frameshift mutations[1]. In addition to these
mutations, there were some reports describing the total
deletion of the AVPR2 gene [2-7], however, the precise
identification of the breakpoints of the fragment deletion
was done in only three reports[4,6,7].
In this study, we ascertained two patients suffering from
congenital NDI in a Chinese family caused by a 5,995-bp
genomic fragment deletion and 3-bp insertion at Xq28,
and this deletion encompassed a complete loss of the
AVPR2 gene and the last exon (exon 22) of the C1 gene,
which is adjacent closely to the AVPR2 gene locus.
Results
The two patients in this Chinese NDI family showed nor-
mal statures, the proband (III-1) was 174 cm height and
80 kg weight, and his young cousin (III-2) was 170 cm
height and 70 kg weight, respectively. Neither of them had
any evidence of mental retardation or significant diseases
other than NDI. All chemical laboratory tests were per-
formed using standard clinical laboratory assays. The
chemical laboratory tests including blood glucose, liver
function, renal function, triglyceride, total cholesterol,
blood electrolyte (potassium, sodium, calcium, phospho-
rus), coagulation parameters (prothrombin time, partial-
throboplastin time) and hemotology (red blood cell
count, hemoglobin, white blood cell count, and platelet
count) were all within reference range (data not shown).
There were no abnormality of electrocardiographic meas-
urements and no abnormality of pituitary by Magnetic
Resonance Imaging (MRI) examinations, and the ultra-
sonographic examinations of urinary system revealed that
there were normalities in size and structure of kidney, ure-
ter and urinary bladder.
Genomic DNAs from the NDI patients and the related
family members were prepared and subjected to PCR
amplification (five overlapping DNA segments) of the
entire coding regions of AVPR2 gene (GenBank accession
number NM_000054). PCRs with all five primer pairs
within the AVPR2 locus yielded five specific fragments of
the expected sizes (422 bp, 480 bp, 450 bp, 476 bp, and
470 bp) for the control subjects, the sequences of these
five fragments were the same as those from GenBank (Fig-
ure 1). However, no corresponding PCR product yielded
with these five primer pairs was observed in the two
patients. In addition, we performed PCR for the PCK1
gene and detected the expected product in all NDI
patients, indicating that PCR amplification was effective
and reliable in every sample (data not shown) and the
entire AVPR2 gene may be deleted in these two patients.
In order to map the deletion breakpoint, we investigated
the presence or absence of several different fragments
around the AVPR2 locus step by step. In these two
patients, with primer pair 7F/7R but not 6F/6R a PCR
product was amplified, suggesting the 5' breakpoint in the
region between primers 6R and 7R. Using the similar strat-
egy, the 3' breakpoint was suspected to be located in
region between sequences of primers 8F and 9F in the
AVPR2 gene. The deletion junction was finally amplified
with the primer pair 7F/9R, giving an approximately 1.1
kb PCR product. The 1.1 kb PCR product, which con-
tained the deletion breakpoint, was then sequenced in
PCR amplification of the coding region of the AVPR2 gene Figure 1
PCR amplification of the coding region of the AVPR2 gene. Five specific fragments covering the AVPR2 gene were 
amplified (see Methods). One example of the different PCR products, which was emplified by the primer pair 1F/1R, is shown 
exemplarily. Only in the control subjects (I-1, I-2, II-1, II-2, II-3, II-4, II-5 and III-3) the specific fragments were detected.
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both directions. The sequence alignment revealed that a
genomic fragment of 5995-bp was deleted and three bases
(GAG) were inserted (Figure 2-A and 2-B). Therefore, the
5' breakpoint was located within intergenic region
between L1CAM gene (GenBank accession number
U52112) and AVPR2 gene, while the 3' breakpoint was
located within intron 21 of the C1 gene (GenBank acces-
sion number NM_001666). The deletion region con-
tained the entire AVPR2 gene and the part of the C1 gene
from intron 21 to exon 22 (Figure 3).
In order to investigate whether a family member had the
same deletion, their genomic DNAs were used as amplifi-
cation templates in a single-plex reaction using the primer
pair 7F/9R. The specific fragments of expected length
(1160 bp) were observed in the mothers of both patients
(II-3 and II-4) and the grandmother (I-2), whereas the
corresponding fragments were not yield in the other fam-
ily members in this NDI pedigree(Figure 4B). These
results showed that the mothers and the grandmother
were heterozygous for the same fragment deletion and
GAG insertion mutation on X chromosome.
Discussion
With the development of microarray technology, numer-
ous copy number variations are identified in the human
genome[8]. Copy number variation is associated with
many normal phenotypic variations and diseases[9]. Most
copy number variations involved diseases are originally
found in Mendelian diseases. In the present study, we
have identified a novel type mutation of 5,995-bp dele-
tion and 3-bp insertion, which leaded to a complete loss
of the AVPR2 gene and the last exon (exon 22) of the C1
gene, in an X-linked congenital NDI family.
The AVPR2 receptor, which is composed of 371 amino
acids, consists of seven transmembrane domains, four
extracellular domains and four cytoplasmic domains, and
belongs to the superfamily of G protein-coupled receptors
(GPCRs) [10-12]. On binding to AVP, the receptor acti-
vates the Gs/adenylate cyclase, and this leads to increased
level of the intracellular cyclic adenosine monophosphate
(cAMP). The elevated cAMP activates protein kinase A and
starts a phosphorylation cascade that promotes the trans-
location of the water channel, aquaporin 2, to the apical
membrane of the renal tubules and collecting tubules.
This results in increasing water resorption[13]. Therefore,
the person will present polyuria if he has abnormal func-
tion or loss-of-function of AVPR2. In our study, the two
patients suffered from NDI were caused by the complete
deletion of AVPR2 gene. The cause of this genomic frag-
ment deletion on chromosome may be the abundant
The sequence analysis of the deletion breakpoints in two patients Figure 2
The sequence analysis of the deletion breakpoints in two patients. A and B represent the sequence of the proband 
(III-1) and the other patient (III-2), respectively. The 3-bp insertion (GAG) is boxed. The 5' breakpoint was upstream of the 
GAG-insertion, while the 3' breakpoint was downstream of this insertion. Sequence alignment with Genbank accession 
number U52112 and NM_001666 revealed a deletion of a 5,995-bp fragment.
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repetitive DNA in the human genome, which is com-
monly suggested that microdeletions arise through mis-
pairing of large duplicated sequences[14].
In our report, besides the entire loss of the AVPR2 gene,
the last exon (exon 22) and part of intron 21 of the C1
gene were also deleted in these two patients. The C1 gene
is in close proximity to the AVPR2 locus and is orientated
in opposite direction to the reading frame of the AVPR2
gene. The C1 gene, being highly expressed in hematopoi-
etic cells, encodes a protein that appears to represent a
member of the increasingly large group of signaling pro-
teins involved in regulation of small GTP binding proteins
of ras superfamily[15]. Based on the domain and func-
tional data, it is suggested that the protein encoded by C1
gene acts as a Rho-GTPase-activating protein
(ARHGAP4)[13], belonging to the large superfamily of
GTPase-activating proteins. The genomic defect in the C1
gene in our study locates the C-terminal portion of
ARHGAP4, which includes consensus sites of transcrip-
tion termination (polyadenylation signals) and consen-
sus sites for mRNA stability. This, at least theoretically, in
a new C terminus due to a frameshift[7]. Consequently, it
was reasonable to suppose that ARHGAP4 expression and
function might be altered in these two patients. However,
the two patients in our study did not present any major
abnormalities besides clearly defined NDI symptoms
caused by deletion of the entire AVPR2 gene. Their electro-
cardiographic measurements, various laboratory tests in
clinical chemistry and hematology were repeatedly nor-
Model of the AVPR2 gene with the chromosomal map of a submicroscopic deletion found in the patients described Figure 3
Model of the AVPR2 gene with the chromosomal map of a submicroscopic deletion found in the patients 
described. The location of the submicroscopic deletion within the q28 region of the chromosome X between the L1CAM and 
C1 genes loci is shown. The upstream breakpoint was identified within the intergenic region between L1CAM and AVPR2 
genes, while the downstream breakpoint was identified within the intron 21 of the C1 gene by PCR screening, resulting in dele-
tion of the whole AVPR2 gene and the last exon (exon22) of the C1 gene. To identify the exact positions of the deletion break-
points, a primer pair 7F/9R was used to amplify interstitial genomic sequence. The 1160-bp fragment was obtained and 
sequenced.
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mal. Coagulation parameters were also within the refer-
ence ranges. These clinical data were similar to the
patients described previously[4,7]. The reason was postu-
lated that the lack of ARHGAP4 function was most likely
compensated by other members of the GAP family[4]. In
addition to the mentioned above, the two patients in our
study showed normal statures and intelligence and had
normal size and structure in kidney, ureter and bladder,
while one patient reported by Schoneberg T showed men-
tal retardation, reducing reading and writing skills[4], and
the other patient reported by Schulz et al. presented an
enlarged bladder and ureter dilatation[7]. The difference
between them might be associated with the degree of
polyuria and hypernatremic dehydration.
As to the female carriers, they are usually phenotypically
normal because of possessing two X chromosomes. How-
ever, approximately 1% of females heterozygous for an
AVPR2 gene mutation may display variable degrees of
polyuria and polydipsia, which has been explained by a
preferential inactivation (skewing) of the X chromosome
bearing the normal AVPR2 allele. Three heterozygote
females in this kindred of NDI have no symptom of poly-
uria and polydipsia.
Conclusion
We have identified a novel type of 5,995-bp deletion and
3-bp (GAG) insertion at Xq28 in two Chinese patients
with NDI, which including the complete loss of the
(A) The pedigree of a Chinese family with congenital NDI Figure 4
(A) The pedigree of a Chinese family with congenital NDI. (The proband is indicated by an arrow); (B) Amplifica-
tion of the mutated allele in family members. The 1160 bp fragment for the presence of the deletion of the AVPR2 gene 
was amplified with the primer pair of 7F/9R. The fragments were observed in number I-2, II-3, II-4, III-1 and III-2, suggesting that 
number I-2, II-3 and II-4 were heterozygous for the same fragment deletion and GAG insertion mutation on X chromosome.
A
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AVPR2 gene and the last exon (exon 22) of the C1 gene,
leading to NDI without other symptoms.
Methods
Patients Profile
The pedigree of this Chinese family with congenital NDI
is shown in Figure 4A. Two patients with congenital NDI
and eight normal persons belonging to this family were
investigated.
The proband (III-1), who was 20 years old, was admitted
to our department for investigation of polydipsia and
polyuria. He was a full-term infant and was delivered une-
ventfully. His parents were unrelated and healthy and had
no history of inheritable diseases. The proband had pre-
sented with severe polydipsia and polyuria since 7
months of age, and he had not been diagnosed and
treated until the age of 20 years old. When he was admit-
ted to our department, he passed 7000~10900 ml urine
per day and the specific gravity of urine was between
1.000 and 1.005. NDI was diagnosed basing on clinical
symptoms, laboratory findings, and failure to increase
urine volume and urinary osmolality after administration
of 5 u vasopressin (Table 1). The urine volume was
reduced about 50% by hydrochlorothiazide treatment.
The proband had a young cousin (III-2), who was 15 years
old and had also presented severe polydipsia and polyuria
since the age of 6 months. He was diagnosed NDI by local
hospital when he was 15 years old, and the polyuria was
reduced significantly by hydrochlorothiazide treatment.
All clinical and laboratory investigations and molecular
genetics had been conducted in agreement with the family
according to Declaration of Helsinki principles. The
patients and their family were explained the purpose of
the study, and their written informed consents were
obtained prior to beginning the study. The research proto-
col and consent forms were approved by the Reviewer
Board and Ethics Committee of Medicine College of
Shanghai Jiaotong University.
AVPR2 gene analysis
Genomic DNA samples from the two patients and the
other eight related normal persons were extracted from
the peripheral blood leucocytes using the Flexi Gene DNA
Kit (QIAGEN, Hilden, Germany) according to the manu-
facturer's protocol. Five overlapping primers were
designed by software of Primer 3 and were used to amplify
the entire coding sequence and their flanking intronic
sequences of AVPR2 gene by PCR. The five oligonucle-
otide primer pairs are as following: 1F: 5' GGA GTT CTG
CGT GTC TGT CTG 3', 1R: 5' AGA CAC ACC CAG AGG
TGA GG 3', 2F: 5' CTC TGC TAG GAG CCA GGA AGT 3',
2R: 5' GCC AGG ATC ATG TAG GAG GAG 3', 3F: 5' GTG
GCT CTG TTC CAA GTG CT 3', 3R: 5' CAC CAG ACT GGC
ATG AAT CTC 3', 4F: 5'GAC TGC TGG GCC TGC TTT3',
4R: 5' CCA GCA ACA TGA GTA GCA CAA 3', 5F: 5' ACC
TCT GGA AGG TGG GTG TAG 3', 5R: 5' TGT CCA GGG
CCA CAC AGT 3'. In addition, the primers used for dele-
tion analysis are shown in Table 2.
The AVPR2 gene was amplified by standard PCR, which
consisted of a 25 μl reaction mixture containing 20 ng
genomic DNA as template, 8 pmol of each primer, 0.75
mM of each deoxynucleoside triphosphate, 5 mM of
MgCl2, 1× PCR buffer and 1.0 u of thermal stable Taq
Polymerase. The PCR was performed with an initial dena-
turation at 95°C for 2 minutes, followed by 35 cycles of
denaturing at 94°C for 40 seconds, annealing at 58°C for
40 seconds and extending at 72°C for 40 seconds, and
then a final extension at 72°C for 10 minutes. PCR prod-
ucts were identified by 1.5% agarose gel electrophoresis
and then were purified by shrimp alkaline phosphatase
(SAP) and exonuclease I (Exon I)[16]. The purified PCR
products were directly sequenced according to standard
methodology on an ABI 3700 DNA automated sequencer
(Applied Biosystems, CA, USA).
In order to ascertain the breakpoint region, further prim-
ers were designed by Primer 3 to amplify flanking
sequence of AVPR2. The sequences of primers are listed in
Table 2. Genomic DNAs of patient III-1 and III-2 were
used as template in PCR with the designed primers and
PCR conditions were as above described. To position the
deletion breakpoint, a long-PCR was carried out to
amplify the region spanning the breakpoint from the
genomic DNAs of patient III-1 and III-2. Amplification
reactions were performed in a total volume of 25 μl con-
taining 0.3 μM of each deoxynucleoside triphosphate, 40
mM Tricine-KOH (pH 8.7 at 25°C), 15 mM KOAc, 3.5
mM Mg(Oac)2, 3.75 μg/ml BSA, 0.005% Tween 20,
0.005% Nonidet-P40, 5 μM of each primer, 80 ng of DNA
and 1× advantage™ 2 Polymerase (Clontech, Palo Alto,
USA). Cycling conditions were as follows: 94°C for 3 min,
followed by 30 cycles of 94°C for 30s, 64°C for 40s and
68°C for 80 seconds, followed by 68°C for 10 min. Long-
PCR products were purified by shrimp alkaline phos-
phatase (SAP) and exonuclease I (Exon I)[16], and then
Table 1: The results of combined water deprivation with vasopressin test of the proband*
Urine volume (L/d) Basal urinary 
osmolality 
(mosmol/L)
Basal Plasma 
osmolality 
(mosmol/L)
urinary osmolality after 
water deprivation 
(mosmol/L)
plasma osmolality after 
water deprivation 
(mosmol/L)
urinary osmolality after 
injecting vasopressin 
(mosmol/L)
plasma osmolality after 
injecting vasopressin 
(mosmol/L)
Proband 7~10.9 90 299 121 318 154 327
* The dosage of vasopressin injected was 5 u.BMC Genetics 2006, 7:53 http://www.biomedcentral.com/1471-2156/7/53
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sequenced in both directions on ABI 3700 DNA auto-
mated sequencer according to the Big-Dye chemistry reac-
tion protocol (Applied Biosystems, CA, USA).
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